<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511715</url>
  </required_header>
  <id_info>
    <org_study_id>9800</org_study_id>
    <nct_id>NCT04511715</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy</brief_title>
  <official_title>Efficacy and Safety of Intravitreal Bevacizumab for the Improvement of Severe Non-proliferative Diabetic Retinopathy Without DME: a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized clinical trial, 100 eyes with nonproliferative diabetic retinopathy will&#xD;
      be included and divided randomly into 2 groups: Intravitreal Bevacizumab group (50 eyes) that&#xD;
      receive 6 bimonthly intravitreal bevacizumab, and control group (50 eyes) that undergo&#xD;
      regular follow-up for Diabetic Retinopathy. Diabetic macular edema (DME) will be treated&#xD;
      independently in all groups by intravitreal bevacizumab. Primary outcome will be the&#xD;
      percentage of patients with progression of 2 or more stages through international diabetic&#xD;
      retinopathy staging. The secondary measures will be changes in best corrected visual acuity&#xD;
      (BCVA) and central macular thickness (CMT), and number of examinations and injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with equal or more than 2 stages of progression in diabetic retinopathy staging</measure>
    <time_frame>12 months</time_frame>
    <description>Multiple fundus photographs interpreted by a single vitreoretinal surgeon who is blind to the study groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Best corrected visual acuity based on ETDRS letter scale and logMAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Central retinal thickness according to macular ocular coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits</measure>
    <time_frame>12 months</time_frame>
    <description>Number of visits in each time point</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Intravitreal Bevacizumab IVB group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>undergo regular follow-up for Diabetic Retinopathy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Bevacizumab IVB</intervention_name>
    <description>Intravitreal Bevacizumab IVB group (50 eyes) that receive 6 bimonthly IVBs within a period of 10 months following the enrollment</description>
    <arm_group_label>Intravitreal Bevacizumab IVB group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow-up with regular examination for determination of DR progression</intervention_name>
    <description>regular examination for determination of DR progression</description>
    <arm_group_label>undergo regular follow-up for Diabetic Retinopathy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of severe NPDR with DRSS score more than 53 with or without diabetic macular&#xD;
             edema&#xD;
&#xD;
          -  Diagnosis of DM (type 1 or 2) with age more than 18 years' old&#xD;
&#xD;
          -  Visual acuity from 20/25 to 20/40 according to Snellen chart examination or more than&#xD;
             69 letters according to ETDRS chart&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of proliferative diabetic retinopathy features including vitreous hemorrhage&#xD;
             or optic disc or retinal neovascularization&#xD;
&#xD;
          -  History of retinal laser photocoagulation&#xD;
&#xD;
          -  Tractional retinal detachment involving the macula&#xD;
&#xD;
          -  Evidence of neovascularization of angle on examination&#xD;
&#xD;
          -  Macular edema due to a cause other than DME&#xD;
&#xD;
          -  Any ocular condition which may change visual acuity during the study&#xD;
&#xD;
          -  History of intravitreal injection of anti-vascular endothelial growth factor agent in&#xD;
             past 3 months&#xD;
&#xD;
          -  History of any use of intravitreal corticosteroid&#xD;
&#xD;
          -  History of major intra-ocular surgery except cataract surgery in the past 6 months&#xD;
&#xD;
          -  History of thromboembolic every in the past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Homayon Nikkhah, MD</last_name>
    <phone>009822591616</phone>
    <email>labbafi@hotmail.com</email>
  </overall_contact>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Head of ophthalmic research center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

